News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs
Japan’s early approval process for cell and gene therapies still suffers from clinical recruitment challenges and a solid manufacturing framework, says regenerative medicine group FIRM.
Biotech Week Boston
Repligen has launched a single-use version of its XCell ATF cell retention system which can reduce implementation costs by as much as 55% compared to its stainless steel equivalent.
The US FDA has approved a quadrivalent formulation of Protein Sciences’ vaccine, Flublok, produced without eggs or the influenza virus.